Results 71 to 80 of about 2,628 (167)

N-nitrosamine risk assessment in pharmaceuticals: Where are we from a regulatory point of view in 2025?

Journal of Pharmaceutical and Biomedical Analysis Open
N-nitrosamines have been a concern for decades due to their potential mutagenicity and widespread occurrence across various matrices. While evidence suggests carcinogenicity in animals, their potential carcinogenicity in humans has prompted their initial
Yue Zhang, Joëlle Widart, Eric Ziemons, Philippe Hubert, Cédric Hubert   +4 more
doaj   +1 more source

Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study. [PDF]

Int J Environ Res Public Health, 2022
Wang CH, Chen II, Chen CH, Tseng YT.
europepmc   +1 more source

N-nitrosodimethylamine (NDMA) contamination of ranitidine products: A review of recent findings. [PDF]

J Food Drug Anal, 2021
Aldawsari FS, Alshehry YM, Alghamdi TS.
europepmc   +1 more source

Nitrosamine contamination of pharmaceuticals: Cases in Japan, formation mechanisms, detection methods, regulatory perspectives, and insights

Journal of Pharmaceutical and Biomedical Analysis Open
In recent years, mutagenic nitrosamines, such as N-nitrosodimethylamine, have been detected in medicine. This has led to global product recalls and long-term supply suspensions by pharmaceutical companies and consequent clinical impacts.
Genichiro Tsuji, Hidetomo Yokoo, Yosuke Demizu, Yasuhiro Abe, Sayaka Masada, Nahoko Uchiyama, Tomoaki Tsutsumi, Eiichi Yamamoto   +7 more
doaj   +1 more source

N-Nitrosodimethylamine [PDF]

, 2005
Sidhartha D. Ray, Harihara M. Mehendale
openaire   +1 more source

N-nitrosodimethylamine-Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users. [PDF]

J Am Heart Assoc, 2022
Mansouri I, Botton J, Semenzato L, Haddy N, Zureik M.   +4 more
europepmc   +1 more source

Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice

Nature Communications
N-Nitrosodimethylamine (NDMA) is a probable human carcinogen found in contaminated pharmaceuticals and drinking water, yet the impact of age on NDMA susceptibility remains poorly understood.
Lindsay B. Volk, Monét Norales, Callie Karjane, Joshua J. Corrigan, Alper J. Alcaraz, Lee J. Pribyl, Nicolette A. Bugher, Megan Blawas, Isabella Dulski, Einthavy Arunachalam, Nina Gubina, Emily Michelsen, Kannammai Pichappan, Natalya Yakimchuk, Matilda Swanson, Duanduan Ma, Stuart S. Levine, Desiree L. Plata, Robert G. Croy, Leona D. Samson, John M. Essigmann, Carole L. Yauk, Sebastian E. Carrasco, Bevin P. Engelward   +23 more
doaj   +1 more source

Molecular origins of mutational spectra produced by the environmental carcinogen N-nitrosodimethylamine and S_N1 chemotherapeutic agents. [PDF]

NAR Cancer, 2023
Armijo AL, Thongararm P, Fedeles BI, Yau J, Kay JE, Corrigan JJ, Chancharoen M, Chawanthayatham S, Samson LD, Carrasco SE, Engelward BP, Fox JG, Croy RG, Essigmann JM.   +13 more
europepmc   +1 more source

Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea. [PDF]

J Clin Med, 2021
Yoon HJ, Kim JH, Seo GH, Park H.
europepmc   +1 more source

Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial.

JAMA, 2021
Florian J, Matta MK, DePalma R, Gershuny V, Patel V, Hsiao CH, Zusterzeel R, Rouse R, Prentice K, Nalepinski CG, Kim I, Yi S, Zhao L, Yoon M, Selaya S, Keire D, Korvick J, Strauss DG.   +17 more
europepmc   +1 more source